Similarly, targeting CTSS activities by using the specific monoclonal antibody Fsn0503 not only attenuates tumor invasion and HUVEC tube formation but also elicits strong antibody-dependent cellular cytotoxicity in tumor cells [15–17]. Here, CTSS is linked to neoplasm.